急性肾损伤生物标志物推荐:急性疾病质量倡议共识会议共识声明
该共识由23名国际重症、肾脏病及相关领域专家在急性疾病质量倡议会议上制定,聚焦急性肾损伤风险评估、预测与预防、诊断病因与管理、进展与肾脏恢复4个领域。通过改良德尔菲流程,基于现有数据形成推荐和共识声明,需90%专家同意方可采纳,并采用GRADE系统分级。最终制定11条生物标志物使用共识声明和14条研究建议。关键建议为联合损伤与功能生物标志物及临床信息识别高风险患者、提高急性肾损伤诊断准确性、改善诊疗流程并辅助管理。现有临床研究证据支持新型生物标志物用于急性肾损伤的预防和管理,但知识缺口仍大,需更多研究。
要点
- 共识建议联合损伤与功能生物标志物及临床信息,用于识别急性肾损伤高风险患者群体。
- 共识建议联合损伤与功能生物标志物及临床信息,以提高急性肾损伤的诊断准确性。
- 共识建议联合损伤与功能生物标志物及临床信息,以改善急性肾损伤的诊疗流程。
- 共识建议联合损伤与功能生物标志物及临床信息,以辅助急性肾损伤的管理。
- 共形成11条生物标志物使用共识声明和14条研究建议,现有证据支持新型生物标志物用于急性肾损伤预防和管理。
适用人群与场景
- 适用于需要急性肾损伤风险评估、预测与预防、诊断病因与管理、进展与肾脏恢复的重症、肾脏病及相关临床场景患者。
处置流程与药物剂量
- 共识建议联合损伤与功能生物标志物及临床信息,用于识别急性肾损伤高风险患者群体。
- 共识建议联合损伤与功能生物标志物及临床信息,以提高急性肾损伤的诊断准确性。
- 共识建议联合损伤与功能生物标志物及临床信息,以改善急性肾损伤的诊疗流程。
- 共识建议联合损伤与功能生物标志物及临床信息,以辅助急性肾损伤的管理。
研究设计与关键结果
- 23名国际重症、肾脏病及相关领域专家在急性疾病质量倡议会议上聚焦4个领域:急性肾损伤风险评估、预测与预防、诊断病因与管理、进展与肾脏恢复。
- 文献检索发现1965年至2019年5月间发表的超过65000篇文章。
- 采用改良德尔菲流程,基于现有数据制定推荐和共识声明,需90%专家同意方可最终采纳。
- 推荐采用GRADE系统分级。
- 最终制定11条生物标志物使用共识声明和14条研究建议。
证据类型、等级与局限
- 证据类型:专家共识(改良德尔菲流程,90%同意阈值),推荐采用GRADE系统分级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为现有临床研究证据支持新型生物标志物用于急性肾损伤的预防和管理。
- 作者认为知识缺口仍大,需更多研究。
指南或共识出处
- 急性疾病质量倡议共识会议共识声明(Recommendations on Acute Kidney Injury Biomarkers From the Acute Disease Quality Initiative Consensus Conference: A Consensus Statement),发表于JAMA Netw Open。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: In the last decade, new biomarkers for acute kidney injury (AKI) have been identified and studied in clinical trials. Guidance is needed regarding how best to incorporate them into clinical practice.
OBJECTIVE: To develop recommendations on AKI biomarkers based on existing data and expert consensus for practicing clinicians and researchers.
EVIDENCE REVIEW: At the 23rd Acute Disease Quality Initiative meeting, a meeting of 23 international experts in critical care, nephrology, and related specialties, the panel focused on 4 broad areas, as follows: (1) AKI risk assessment; (2) AKI prediction and prevention; (3) AKI diagnosis, etiology, and management; and (4) AKI progression and kidney recovery. A literature search revealed more than 65 000 articles published between 1965 and May 2019. In a modified Delphi process, recommendations and consensus statements were developed based on existing data, with 90% agreement among panel members required for final adoption. Recommendations were graded using the Grading of Recommendations, Assessment, Development and Evaluations system.
FINDINGS: The panel developed 11 consensus statements for biomarker use and 14 research recommendations. The key suggestions were that a combination of damage and functional biomarkers, along with clinical information, be used to identify high-risk patient groups, improve the diagnostic accuracy of AKI, improve processes of care, and assist the management of AKI.
CONCLUSIONS AND RELEVANCE: Current evidence from clinical studies supports the use of new biomarkers in prevention and management of AKI. Substantial gaps in knowledge remain, and more research is necessary.
参考来源
- Ostermann M, Zarbock A, Goldstein S, et al. Recommendations on Acute Kidney Injury Biomarkers From the Acute Disease Quality Initiative Consensus Conference: A Consensus Statement. JAMA Netw Open. 2020. PMID: 33021646. doi:10.1001/jamanetworkopen.2020.19209
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。